Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
News May 20, 2010
Evotec AG has announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.
The compound, which was discovered and optimized within the alliance, is being developed as a novel treatment for neuropathic pain, a disease caused by damage or dysfunction of the nervous system and affecting up to 7-8% of the world’s population.
The alliance has involved working on multiple high priority targets across key therapeutic areas and has recently been expanded for four further years to include oncology. So far it has resulted in eight milestone payments from multiple programmes.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “This clearly validates our strategy of creating value for our partners and further emphasises our expertise in providing most efficient integrated drug discovery solutions for our collaborators. We are looking forward to advancing other exciting projects towards the clinic as part of this innovative alliance.”
12th Edition of International Conference on Infectious Diseases
Apr 22 - Apr 23, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019